**Name of journal: World Journal of Nephrology**

**ESPS Manuscript NO: 11962**

**Columns: MINIREVIEWS**

**Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions**

Qayyum A *et al*. Biocompatible, glucose-free PD solutions

Ahad Qayyum, Elizabeth Ley Oei, Klara Paudel, Stanley L Fan

**Ahad Qayyum, Klara Paudel,** **Stanley L Fan,** Department of Renal Medicine and Transplantation, The Royal London Hospital,Barts Health NHS Trust, London E1 1BB, United Kingdom

**Elizabeth Ley Oei,** Department of Renal Medicine and Transplantation, Singapore General Hospital, Singapore 169608, Singapore

**Author contributions:** Qayyum A and Fan LS designed the mini-review, generated the tables and figure and co-wrote the manuscript; Oei LE and Paudel K contributed to the data collection and writing of the manuscript.

**Correspondence to: Dr. Stanley L Fan,** Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London E1 1BB,United Kingdom. [s.fan@qmul.ac.uk](mailto:s.fan@qmul.ac.uk)

**Telephone:** +44-20-35942674 **Fax:** +44-20-35942691

**Received:** June 14, 2014 **Revised:** October 7, 2014

**Accepted:** November 17, 2014

**Published online:**

**Abstract**

A major concern inhibiting some clinicians from embracing peritoneal dialysis (PD) as the preferred first modality of dialysis is the effects of peritoneal dialysis solutions on the peritoneal membrane. These anatomical and functional changes predispose to complications like peritonitis, encapsulating peritoneal sclerosis and ultrafiltration failure. In recent years, “biocompatible” and glucose-sparing PD regimens have been developed to minimize damage to the peritoneal membrane. Can the use of these more expensive solutions be justified on current evidence? In this review of the literature, we explore how we may individualize the prescription of biocompatible PD fluid.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Individualized prescription; Biocompatibility; Peritoneal dialysis; Glucose degradation products; Peritonitis; Ultrafiltration failure; Residual renal function

**Core tip:** There is increasing evidence of benefit for using biocompatible and non-glucose based peritoneal dialysis (PD) fluids. However, cost remains an impediment and perhaps there are selected groups of patients where the cost can be justified. We suggest that biocompatible solutions should be considered for patients with residual renal function and/or expected to remain on PD for a long period. They are particularly helpful for patients with drain-in pains. The targeting of diabetic patients for non-glucose solutions is intriguing given the recent IMPENDIA/EDEN study although vigilance is required to minimize unaware hypoglycemia. It remains to be seen if PD nephrologists are willing to take the same leap of faith that our hemodialysis (HD) colleagues took when they moved from Acetate-based HD solutions to Bicarbonate dialysate.  It is possible that economies of scale will reduce the cost of the biocompatible solutions if we use them more frequently.

Qayyum A, Oei EL, Paudel K, Fan SL. Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions. *World J Nephrol* 2014, In press

**INTRODUCTION**

Peritoneal dialysis (PD) has been a popular modality of renal replacement therapy since it was introduced in 1978[1]. In comparison to hemodialysis (HD), PD provides a more gradual and continuous method of fluid & solute clearance, with improved preservation of residual renal function and minimal cardiac stress. PD is at least equivalent in terms of survival benefits in the initial phase of dialysis vintage[2]. Furthermore, PD is more cost effective than HD, especially when reduced erythropoietin stimulatory agent requirement and patient transport cost savings are considered[3].

Common complications of PD include peritonitis, technique and ultrafiltration failure.It has been proposed that newer “biocompatible” and “non-glucose” containing PD fluids can reduce these complications[4]. However, these newer PD solutions are more expensive, and the potential cost advantage of PD over HD may be attenuated. We have reviewed the literature to determine if the additional cost of these newer solutions can be offset by reducing complication rates.

It is generally accepted that conventional PD fluids alter the functional and anatomical integrity of the peritoneal membrane over time[5,6]. Glucose degradation products (GDPs), high lactate and low pH levels have been implicated in the pathogenesis of adverse dynamic changes in the peritoneal membrane[7], which then predispose to complications like peritonitis, technique failure etc[8].

Biocompatible PD fluids are produced in multi-compartmented bags that separately store the acidic glucose solution and the bicarbonate buffer solution. This allows the glucose component to be heat sterilized at a low pH thus causing minimal or no caramelization and GDP generation[9]. At the point of use, the acidic glucose compartment is mixed together with the buffer solution to produce a more physiological pH solution, with minimal lactate and GDP concentrations.

**ALTERNATIVES TO GLUCOSE AS OSMOTIC AGENTS**

Glucose remains a popular osmotic agent in conventional PD solutions due to its low cost, relative safety and effectiveness. Increasing glucose concentration allows for greater ultrafiltration due to the larger osmotic gradient. However, increasing glucose concentrations also means increased glucose absorption, which may result in metabolic abnormalities like hyperglycemia, hyperinsulinemia, obesity and hyperlipidemia[10]. Non-glucose based osmotic agents such as icodextrin (used in Extraneal solution) and amino acids (used in Nutrineal solution) are often used in glucose-sparing regimens to reduce the metabolic impact of glucose absorption. The icodextrin molecule is large sized and does not cross the membrane easily, thus producing a prolonged osmotic gradient and sustained ultrafiltration. The enhanced ultrafiltration achieved with Extraneal results in better fluid balance with improved blood pressure control[11], and a reduction in left ventricular mass[12].

Nutrineal is an amino acid based PD solution which is generally considered equivalent to a 1.36% glucose bag with respect to osmotic power. Although the pH of the solution is 5.5 (low), it contains no glucose and hence is considered biocompatible. No study has shown any mortality benefit with this solution but improvements in nutritional parameters like albumin, transferrin and protein catabolic rate has been observed in some malnourished PD patients[13,14]. Both these non-glucose based PD solutions are licensed to be used once a day.

**COST OF BIOCOMPATIBLE PD SOLUTIONS**

Table 1 illustrates the cost difference between the various PD solutions. For convenience sake we have included the trade name of the PD fluids most commonly used in the United Kingdom. The catalogue prices of the non-conventional solutions are approximately 50% more expensive than the conventional ones. In the United Kingdom, based on these catalogue prices, continuous ambulatory peritoneal dialysis compromising of daily 4 exchanges (CAPD x4) of Dianeal would cost £5650/yr, but x2 Physioneal, Nutrineal, Extraneal would cost £10860/yr. The incremental cost of switching a patient on automated peritoneal dialysis (APD) from Dianeal to biocompatible glucose sparing regimen is similar. The cost incurred using 4 cycles of Dianeal (1.36%) overnight followed by last fill Dianeal (2.27%) is estimated to be £9420/yr. A switch to 3 cycles of Physioneal, 1 cycle of Nutrineal and last fill Extraneal would cost an extra £5000/yr (Table 2).

When extrapolating to a PD program of 150 patients the additional cost of prescribing biocompatible, glucose sparing regimen equates to £0.75M/yr. This calculation is somewhat spurious as it is based the on United Kingdom catalog prices which is not the actual price charged to the National Health Service (NHS). Nevertheless, as a comparator, the annual salary of a Band 6 nurse in United Kingdom ranges between £25700 to £34500. These figures present a significant dilemma as the same PD program could possiblyemploy 20 additional fully trained nurses at equivalent cost of changing to glucose sparing biocompatible fluids.

**EVIDENCE OF BENEFIT AND USE OF BIOCOMPATIBLE PD SOLUTIONS**

Faced with the reality of current financial constraints can we individualise the use of biocompatible PD fluids?

The balANZ trial[15] was a large well conducted RCT exploring the clinical benefits of biocompatible solutions. Using biocompatible fluids, a significant 33% reduction in peritonitis rates was achieved although other studies have not yielded similar results. We have to consider if employing additional nurses would be more cost effective than biocompatible solutions in reducing peritonitis rates[16].

The balANZ study also suggested that biocompatible solutions may better preserve residual renal function (RRF). Although the primary end point did not reach statistical significance, the rate of decline of RRF was lower in the biocompatible PD fluid arm and time to anuria which was a secondary end-point did reach statistical significance. The importance of delaying onset of anuria should not be underestimated and would support using these more expensive solutions in patients with residual renal function.

One of the strongest drivers for the use of biocompatible solutions is the hope that PD membrane will be preserved, thereby delaying PD technique failure and reducing the development of encapsulating peritoneal sclerosis (EPS). Dialysate concentration of Cancer Antigen 125 (CA-125) is proposed to be an indicator of peritoneal mesothelial cell health[17]. There is evidence to suggest that biocompatible solutions preserve CA-125 levels, implying that they might prevent peritoneal membrane damage induced by the bioincompatible nature of the PD solutions[18,19].Those most at risk of EPS may benefit from using biocompatible solutions. The incidence of EPS complication increases with time on PD[20]. There is consensus that EPS is very rare in people who were on PD for less than 3-4 years. The Pan-Thames EPS study[21] showed that more than 70% of the patients who developed EPS had a PD vintage of more than 5 years. If one is to use biocompatible solutions to reduce EPS risk, it should be prescribed at outset of PD. One might argue that elderly patients with high co-morbidity and short life-expectancy are unlikely to develop this complication. Perhaps more controversially, young patients with good match prognosis index for transplantation (especially patients with live donors) are also less likely to remain on PD long enough to develop EPS.

Infusion pain with PD fluids is known to affect treatment compliance and quality of life[22]. This pain is ascribed to the low pH of conventional PD solutions and the use of biocompatible PD fluids instead has shown to alleviate this discomfort in a randomized controlled trial[23].

**GLUCOSE BASED VERSUS NON-GLUCOSE BASED PD FLUIDS**

The use of hypertonic 3.86%-glucose bags appears to precede the development of ultrafiltration failure (UF) and impaired osmotic conductance which are important predictors of PD technique failure and EPS[24]. Replacing 3.86% hypertonic solutions with Extraneal would be a reasonable strategy. The role of icodextrin for patients who have high transport characteristics exhibiting UF failure is well established, and recommended in the International Society of Peritoneal Dilaysis (ISPD) guidelines. However, it is not clear if reducing glucose exposure further by substituting Nutrineal for 1.36% glucose solutions will have clinically significant effects on peritoneal membrane preservation. Whilst inadequate solute clearance and ultrafiltration failure are undoubted causes of PD technique failure, patient and carer “burn out” is probably equally important. In this situation, biocompatible solutions will not help but diverting resources to providing more nursing support may be more effective in helping such patients continue on PD.

There are other obvious reasons for minimizing glucose load in the PD solution. Li et al (on behalf of the IMPENDIA and EDEN study groups)[25] reported a significant improvement in glycemic and lipid control with the use of glucose sparing PD fluids in the diabetic population. Could better glycaemic control have been achieved through more meticulous diabetic treatment if the additional resources were devoted to providing a comprehensive diabetic service? We suggest an additional caveat: not only should we be concerned about hyperglycaemia but hypoglycemia unawareness might be more dangerous leading to cardiac instability (an association between unaware hypoglycaemia and prolonged QT-dispersion has been found in non-dialysis patients[26]). Hypoglycaemia unawareness is certainly something that we have found in diabetic patients that undergo routine continuous glucose monitoring. Figure 1 provides an example of diurnal hourly variations in interstitial glucose concentrations in a diabetic patient using nocturnal icodextrin to minimize overnight glucose exposure.

**CONCLUSION**

It is very ironic to note that hemodialysis faced a similar dilemma when a transition from acetate to bicarbonate buffered dialysate was proposed. Prescribing bicarbonate dialysate was equally controversial as it was more expensive and generally all the supportive data came from *in vitro* studies while *in vivo* studies provided very little support. Nevertheless, a calculated rational leap of faith was taken and over time bicarbonate buffered HD dialysate has become cost-effective. Furthermore, the superiority of bicarbonate over acetate-based buffer was demonstrated during this time.Although we strongly believe in the potential benefits of PD biocompatible fluids, we acknowledge the pragmatic hesitancy of our colleagues due to associated high premium costs. In such a stalemate situation an approach to individualizing the prescription of biocompatible PD solutions is sensible. There is evidence to support its use in selected patients groups such as those with residual renal function with good life expectancy or patients with drain-in pain. The use of non-glucose PD solutions to improve diabetic control is perhaps more controversial but one hopes that cost will fall as uptake of these solutions increase. We are quite hopeful that in the imminent future the story of biocompatible PD fluids will have a similar conclusion to that of the bicarbonate buffered dialysate in hemodialysis.

**REFERENCES**

1 **Popovich RP**, Moncrief JW, Nolph KD. Continuous ambulatory peritoneal dialysis. *Artif Organs* 1978; **2**: 84-86 [PMID: 687024]

2 **McDonald SP,** Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. *J Am Soc Nephrol* 2009; **20:** 155-163 [PMID: 19092128 DOI: 10.1681/ASN.2007111188]

3 **Blake PG**. Integrated end-stage renal disease care: the role of peritoneal dialysis. *Nephrol Dial Transplant* 2001; **16** Suppl 5: 61-66 [PMID: 11509687 DOI: 10.1093/ndt/16.suppl\_5.61]

4 **Chung SH**, Stenvinkel P, Bergström J, Lindholm B. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? *Perit Dial Int* 2000; **20** Suppl 5: S57-S67 [PMID: 11229614]

5 **Williams JD**, Craig KJ, von Ruhland C, Topley N, Williams GT; Biopsy Registry Study Group. The natural course of peritoneal membrane biology during peritoneal dialysis. *Kidney Int Suppl* 2003; **(88):** S43-S49 [PMID: 14870877 DOI: 10.1046/j.1523-1755.2003.08805.x]

6 **Williams JD**, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT; Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. *J Am Soc Nephrol* 2002; **13**: 470-479 [PMID: 11805177]

7 **Tauer A**, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, Pischetsrieder M. Formation of advanced glycation end products during CAPD. *Am J Kidney Dis* 2003; **41**: S57-S60 [PMID: 12612954 DOI: 10.1053/ajkd.2003.50086]

8 **Davies SJ**, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. *Nephrol Dial Transplant* 1996; **11**: 498-506 [PMID: 8671821 DOI: 10.1093/oxfordjournals.ndt.a027318]

9 **Rippe B**, Simonsen O, Wieslander A, Landgren C. Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. *Perit Dial Int* 1997; **17**: 27-34 [PMID: 9068019]

10 **Delarue J**, Maingourd C. Acute metabolic effects of dialysis fluids during CAPD. *Am J Kidney Dis* 2001; **37**: S103-S107 [PMID: 11158872 DOI: 10.1053/ajkd.2001.20762]

11 [**Finkelstein F**](http://www.ncbi.nlm.nih.gov/pubmed?term=Finkelstein%20F%5BAuthor%5D&cauthor=true&cauthor_uid=15625070)**,** [Healy H](http://www.ncbi.nlm.nih.gov/pubmed?term=Healy%20H%5BAuthor%5D&cauthor=true&cauthor_uid=15625070), [Abu-Alfa A](http://www.ncbi.nlm.nih.gov/pubmed?term=Abu-Alfa%20A%5BAuthor%5D&cauthor=true&cauthor_uid=15625070), [Ahmad S](http://www.ncbi.nlm.nih.gov/pubmed?term=Ahmad%20S%5BAuthor%5D&cauthor=true&cauthor_uid=15625070), [Brown F](http://www.ncbi.nlm.nih.gov/pubmed?term=Brown%20F%5BAuthor%5D&cauthor=true&cauthor_uid=15625070), [Gehr T](http://www.ncbi.nlm.nih.gov/pubmed?term=Gehr%20T%5BAuthor%5D&cauthor=true&cauthor_uid=15625070), [Nash K](http://www.ncbi.nlm.nih.gov/pubmed?term=Nash%20K%5BAuthor%5D&cauthor=true&cauthor_uid=15625070), [Sorkin M](http://www.ncbi.nlm.nih.gov/pubmed?term=Sorkin%20M%5BAuthor%5D&cauthor=true&cauthor_uid=15625070), [Mujais S](http://www.ncbi.nlm.nih.gov/pubmed?term=Mujais%20S%5BAuthor%5D&cauthor=true&cauthor_uid=15625070). Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. [*J Am Soc Nephrol*](http://www.ncbi.nlm.nih.gov/pubmed/?term=Finkelstein%2C+F.%2C+et+al.%2C+Superiority+of+icodextrin+compared+with+4.25%25+dextrose+for+peritoneal+ultrafiltration.+J+Am+Soc+Nephrol%2C+2005.+16%282%29%3A+p.+546-54.) 2005 **16:** 546-554 [PMID: 15625070 DOI: [10.1681/ASN.2004090793](http://dx.doi.org/10.1681/ASN.2004090793" \t "_blank)]

12 **Konings CJ**, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hoorntje SJ, Wolters J, van der Sande FM, Leunissen KM. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. *Kidney Int* 2003; **63**: 1556-1563 [PMID: 12631373 DOI: 10.1046/j.1523-1755.2003.00887.x]

13 **Kopple JD**, Bernard D, Messana J, Swartz R, Bergström J, Lindholm B, Lim V, Brunori G, Leiserowitz M, Bier DM. Treatment of malnourished CAPD patients with an amino acid based dialysate. *Kidney Int* 1995; **47**: 1148-1157 [PMID: 7783413 DOI: 10.1038/ki.1995.164]

14 **Taylor GS**, Patel V, Spencer S, Fluck RJ, McIntyre CW. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. *Clin Nephrol* 2002; **58**: 445-450 [PMID: 12508967 DOI: 10.5414/CNP58445]

15 **Johnson DW,** Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan SH, Voss D; balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. *J Am Soc Nephrol* 2012; **23:** 1097-1107 [PMID: 22440906 DOI: 10.1681/ASN.2011121201]

16 **Cox SD**, Steddon S, Mallinder S, Fan SL, Punzalan S. Re-training and switching of PD system to reduce recurrent gram-positive PD peritonitis. *J Ren Care* 2006; **32**: 198-201 [PMID: 17345978 DOI: 10.1111/j.1755-6686.2006.tb00022.x]

17 **Visser CE**, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. *Nephrol Dial Transplant* 1995; **10**: 64-69 [PMID: 7724031]

18 **le Poole CY**, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. *Perit Dial Int* 2005; **25** Suppl 3: S64-S68 [PMID: 16048260]

19 **Weiss L**, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, Ahlmén J, Larsson R, Ingman B, Simonsen O, van Hamersvelt HW, Johansson AC, Hylander B, Mayr M, Nilsson PH, Andersson PO, De los Ríos T. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. *Perit Dial Int* 2009; **29**: 647-655 [PMID: 19910566]

20 **Kavanagh D**, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999-2002). *Nephrol Dial Transplant* 2004; **19**: 2584-2591 [PMID: 15304559 DOI: 10.1093/ndt/gfh386]

21 **Balasubramaniam G**, Brown EA, Davenport A, Cairns H, Cooper B, Fan SL, Farrington K, Gallagher H, Harnett P, Krausze S, Steddon S. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. *Nephrol Dial Transplant* 2009; **24**: 3209-3215 [PMID: 19211652 DOI: 10.1093/ndt/gfp008]

22 [**Feriani M**](http://www.ncbi.nlm.nih.gov/pubmed?term=Feriani%20M%5BAuthor%5D&cauthor=true&cauthor_uid=9844152)**,** [Kirchgessner J](http://www.ncbi.nlm.nih.gov/pubmed?term=Kirchgessner%20J%5BAuthor%5D&cauthor=true&cauthor_uid=9844152), [La Greca G](http://www.ncbi.nlm.nih.gov/pubmed?term=La%20Greca%20G%5BAuthor%5D&cauthor=true&cauthor_uid=9844152), [Passlick-Deetjen J](http://www.ncbi.nlm.nih.gov/pubmed?term=Passlick-Deetjen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=9844152). “Randomized long-term evaluation of bicarbonate-buffered CAPD solution.” [*Kidney Int*](http://www.ncbi.nlm.nih.gov/pubmed/?term=M.+Feriani%2C+J.%2C+et+al.%2C+%E2%80%9CRandomized+long-term+evaluation+of+bicarbonate-buffered+CAPD+solution.%E2%80%9D+Kidney+Int.+1998%3B+54%285%29%3A+1731%E2%80%931738.) 1998; **54:** 1731-1738 [PMID:9844152 DOI: [10.1046/j.1523-1755.1998.00167.x](http://dx.doi.org/10.1046/j.1523-1755.1998.00167.x" \t "_blank)]

23 [**Mactier RA**](http://www.ncbi.nlm.nih.gov/pubmed?term=Mactier%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=9551418)**,** [Sprosen TS](http://www.ncbi.nlm.nih.gov/pubmed?term=Sprosen%20TS%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Gokal R](http://www.ncbi.nlm.nih.gov/pubmed?term=Gokal%20R%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Williams PF](http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20PF%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Lindbergh M](http://www.ncbi.nlm.nih.gov/pubmed?term=Lindbergh%20M%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Naik RB](http://www.ncbi.nlm.nih.gov/pubmed?term=Naik%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Wrege U](http://www.ncbi.nlm.nih.gov/pubmed?term=Wrege%20U%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Gröntoft KC](http://www.ncbi.nlm.nih.gov/pubmed?term=Gr%C3%B6ntoft%20KC%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Larsson R](http://www.ncbi.nlm.nih.gov/pubmed?term=Larsson%20R%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Berglund J](http://www.ncbi.nlm.nih.gov/pubmed?term=Berglund%20J%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Tranaeus AP](http://www.ncbi.nlm.nih.gov/pubmed?term=Tranaeus%20AP%5BAuthor%5D&cauthor=true&cauthor_uid=9551418), [Faict D](http://www.ncbi.nlm.nih.gov/pubmed?term=Faict%20D%5BAuthor%5D&cauthor=true&cauthor_uid=9551418). “Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.” [*Kidney Int*](http://www.ncbi.nlm.nih.gov/pubmed/?term=R.+A.+Mactier.%2C+et+al.%2C+%E2%80%9CBicarbonate+and+bicarbonate%2Flactate+peritoneal+dialysis+solutions+for+the+treatment+of+infusion+pain.%E2%80%9D+Kidney+Int.+1998%3B+53%284%29%3A+1061%E2%80%931067.)1998; **53:** 1061-1067 [PMID:9551418 DOI: [10.1111/j.1523-1755.1998.00849.x](http://dx.doi.org/10.1111/j.1523-1755.1998.00849.x" \t "_blank)]

24 **Davies SJ**, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. *J Am Soc Nephrol* 2001; **12**: 1046-1051 [PMID: 11316864]

25 **Li PK**, Culleton BF, Ariza A, Do JY, Johnson DW, Sanabria M, Shockley TR, Story K, Vatazin A, Verrelli M, Yu AW, Bargman JM. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. *J Am Soc Nephrol* 2013; **24**: 1889-1900 [PMID: 23949801 DOI: 10.1681/ASN.2012100987]

26 **Chow E**, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. *Diabetes* 2014; **63**: 1738-1747 [PMID: 24757202 DOI: 10.2337/db13-0468]

**P-Reviewer:** Olowu WA, Shrestha BM **S-Editor:** Tian YL

**L-Editor: E-Editor:**

**Table 1 Catalog prices of different peritoneal solutions**


|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | United Kingdom (£) | | Singapore ($) | | Pakistan (Rs) | |
| CAPD Fluid | | | | | | |
| Conventional CAPD  2 litre bag |  | |  | |  | |
| Dianeal (1.5%) | 3.87 | | 10.66 | | 774 | |
| Staysafe (1.5%) | 4.24 | | 10.98 | | 812 | |
| Biocompatible CAPD 2 litre bag | £ | Increment (%) | Sing $ | Increment (%) | Rs | Increment (%) |
| Physioneal | 7.32 | 89 | 12.50 | 17 | 1464 | 89 |
| Nutrineal | 8.50 | 120 | 14.00 | 31 | 1785 | 131 |
| Extraneal | 6.60 | 70 | 12.30 | 16 | 1200 | 55 |
| Balance | 4.63 | 9 | 12.10 | 10 | 1020 | 26 |
| Automated PD Fluid | | | | | | |
| Conventional APD  5 litre bag |  |  |  |  |  |  |
| Dianeal (1.5%) | 8.60 | | 28 | | 1400 | |
| Sleepsafe (1.5%) | 7.80 | | 28 | | 1450 | |
| Biocompatible APD  5 litre bag |  | Increment (%) |  | Increment (%) |  | Increment (%) |
| Physioneal | 12.20 | 42 | 39 | 39 | 2200 | 57 |
| Sleep balance | 12.50 | 60 | 40.50 | 45 | 2350 | 62 |

CAPD : Continuous ambulatory peritoneal dialysis; APD: Automated peritoneal dialysis; PD: Peritoneal dialysis. Source: Fresenius Dialysis Product Catalogue 2013 revised (United Kingdom, Singapore & South Asia); Baxter PD Product List 2014 (United Kingdom, Singapore &Pakistan).

**Table 2 Estimated annual cost of peritoneal dialysis fluids based on United Kingdom catalog prices**

|  |  |  |
| --- | --- | --- |
|  | **United Kingdom (£)** | **Increment (%)** |
| **CAPD** | | |
| Dianeal (1.5%) x 4 | £5650 | **--** |
| 2 x Dianeal, Nutrineal, Extraneal | 8340 | 48 |
| 2 x Physioneal, Extraneal, Nutrineal | 10860 | 92 |
| APD | | |
| Dianeal: 1.36% (x 4 cycles) with last fill of 2.27% | £9420 | **--** |
| Dianeal, Nutrineal, Extraneal: (x 3 cycles 1.36%, 1 cycle Nutrineal) with last fill Extraneal | 11790 | 25 |
| Physioneal, Nutrineal, Extraneal(x 3 cycles 1.36%, 1 cycle Nutrineal) with last fill Extraneal | 14420 | 53 |

CAPD : Continuous ambulatory peritoneal dialysis; APD: Automated peritoneal dialysis.



**Time (h)**

Blood glucose concentration

**Figure 1 Continuous Glucose monitoring (6 d) of a Diabetic patient on Peritoneal Dialysis using Extraneal at night (22:00 to 06:00) not only showing hyperglycemia during the day (after 10am) when glucose PD solutions used, but also showing significant and regular episodes of hypoglycemia (unaware) suffered by the patient overnight.** Continuous Glucose Monitoring demonstrates the merits and risk of using non-glucose based PD solutions (Extraneal). On one hand the overnight Extraneal dwell (from 22:00 to 06:00 h the next day) controlled the blood sugar effectively in comparison to the glucose based PD fluid dwell (from 06:00 till 22:00 hours the same day). On the other hand Extraneal is putting the patient at risk of hypoglycemia (between 05:00 and 08:00 h). It is noteworthy that diabetic end stage renal disease patients have an increase incidence of hypoglycemia unawareness.